Invivyd, Inc. (IVVD)
(Delayed Data from NSDQ)
$2.42 USD
+0.20 (9.01%)
Updated May 1, 2024 04:00 PM ET
After-Market: $2.43 +0.01 (0.41%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Invivyd, Inc. [IVVD]
Reports for Purchase
Showing records 1 - 12 ( 12 total )
Company: Invivyd, Inc.
Industry: Medical - Biomedical and Genetics
Potential Blockbuster PEMGARDA Receives Emergency Use Authorization as COVID-19 Prophylactic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Invivyd, Inc.
Industry: Medical - Biomedical and Genetics
Potential Blockbuster VYD222 on Track for EUA Approval as COVID-19 Prophylactic; Upping Price Target to $15; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Invivyd, Inc.
Industry: Medical - Biomedical and Genetics
VYD222 Appears on Track to Clear Phase 3 Hurdle in COVID-19 Prevention Based on Initial Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Invivyd, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; VYD222 Phase 3 COVID-19 Data on Track for Late 2023 or Early 2024 with EUA Filing to Follow; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Invivyd, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Invivyd, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; VYD222 Impresses in Phase 1; Phase 3 Program Expected to Generate Initial Data by 4Q23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Invivyd, Inc.
Industry: Medical - Biomedical and Genetics
Further Data Emerges in Phase 1 Trial Evaluating VYD222, Supporting Advancement to a Pivotal Program in COVID-19
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Invivyd, Inc.
Industry: Medical - Biomedical and Genetics
Accelerated Pathway to Approval of VYD222 Emerges; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Invivyd, Inc.
Industry: Medical - Biomedical and Genetics
VYD222 Clears Phase 1 Hurdle in COVID-19 Program, Supporting Advancement to Potential Pivotal Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Invivyd, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; COVID-19 Program VYD222 Phase 1 Data on Track for 2Q23; Phase 3 Program Expected in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Invivyd, Inc.
Industry: Medical - Biomedical and Genetics
Management Meeting Highlights Blockbuster Potential of VYD222 in Prevention or Early Treatment of COVID-19; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Invivyd, Inc.
Industry: Medical - Biomedical and Genetics
Prevent Defense: Positioned for Success in COVID-19 Prophylaxis Market; Initiate With a Buy and $5 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
|